← boardnext 2027-06next 2027-09-01
HUMA
Humacyte, Inc.distress 4/10 · elevated risk$0.65+1%today-76% from 52w high
Lead: Trauma
Revenue
pre-revenue
Liquidity
$149M
Runway
1.5 yrs
Shares 1y
+40%
Price & events
-41.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.2%
1D
-1.1%
1W
-6.7%
1M
-7.8%
3M
-37.8%
6M
-76.1%
1Y
-92.1%
2Y
-93.5%
5Y
-93.6%
All
Overview
- Market Cap
- $144.96M
- Enterprise Value
- $132.29M
- Volume
- 251.17K
- 52 Week Range
- $0.57 – $2.73
- Total Shares
- 222.02M
- Float Shares
- 196.13M
- Short %
- 11.79%
- % Held by Insiders
- 7.51%
- % Held by Institutions
- 22.31%
- RVOL
- 0.02x
- Beta
- 2.52
Pipeline stages · 2 programs
Acellular Tissue Engineered Vessel (ATEV)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Human Acellular Vessel (HAV)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 3 | Acellular Tissue Engineered Vessel (ATEV)rmatfast track | End Stage Renal Disease (ESRD) | — | active not recruiting |
| 2027-09-01 Estimated 50% readout ~2027-11-15 | Phase 2/3 | Human Acellular Vessel (HAV) | Trauma, Vascular System Injury | — | active not recruiting |
Catalyst news & presentations · 8
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)ATEV · Plan to file supplemental BLA with FDA for ATEV in female dialysis accessSEC 8-K
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
- evening of June 11, 2026 at SVS VAM in Bostonconferencedata presentationsecondaryPhase 3ATEV · Presentation of V012 Phase 3 results at Society for Vascular Surgery's Vascular Annual MeetingSEC 8-K
- 2026-06-05fda agreementRegained compliance with Nasdaq $1.00 minimum bid price rule.SEC 8-K
- 2026-04-21partnershipSymvess · Amended distribution agreement with Fresenius to regain ex-U.S. commercialization rights; will pay low-single-digit royalties.SEC 8-K
- March 16, 2026regulatory submissionFiled (NDA/BLA)Symvess · Filed MAA with Ministry of Health of Israel for Symvess for vascular trauma indication.SEC 8-K
- 2026-03-04partnershipSymvess · Received minimum purchase commitment of $1.48M from KSA entity and exclusive negotiations for joint venture through July 2, 2026.SEC 8-K
- March 27, 2025trial initiationsecondaryExpected closing of underwritten public offering of common stock.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 222,019,108 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $2 (+214% upside) · 5 analysts
- 2026-06-17TD CowenBuy
- 2026-06-16BTIGBuy
- 2026-06-11HC Wainwright & Co.Buy
- 2026-06-08BTIGBuy
- 2026-06-01BenchmarkSpeculative Buy
- 2026-05-26HC Wainwright & Co.Buy
Competitors — Trauma
Recent news
- 2026-07-21Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
- 2026-07-20Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
- 2026-07-20Enterprise value to EBIT forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
- 2026-07-14Two Kidney Specialists Join Humacyte Ahead of Planned Dialysis Access - Stock Titan
- 2026-07-14Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
- 2026-07-13Fresenius to sell 5M Humacyte (HUMA) shares under Rule 10b5-1 plan - Stock Titan
- 2026-06-30Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
- 2026-06-28Enterprise value to revenue forward of Humacyte, Inc. – NASDAQ:HUMA - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.